author-photo

Nuria Quintana

Celgene

7

Papers

515

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

2016 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (81)
Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis

2016 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival

2014 Blood
Show All
- Source
- Cite
- Save
Citations (9)
Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM

2011 Blood
Show All
- Source
- Cite
- Save
Citations (5)
Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

2010 Blood
Show All
- Source
- Cite
- Save
Citations (29)
Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (39)